Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Page 2 of 30
Oct 13, 2026The result cuts against the momentum that had lifted sentiment across mRNA cancer vaccines after Merck & Co. and Moderna reported phase 3 data in August. BioNTech is now asking investors to accept a more difficult immunotherapy thesis: that an mRNA regimen can fail on progression-free survival and still earn its place on overall survival.
Oct 13, 2026The decision shows how quickly degrader portfolios are being triaged even after a program gets through manufacturing and clinical-hold issues. For Nurix, the signal is that platform promise is no substitute for asset selection, and the company now has one clearly prioritized BTK path heading into phase 3.
Oct 13, 2026Pfizer will provide an upfront commitment plus research, development and sales milestones under an agreement that could exceed $500 million, with Enodia also eligible for tiered royalties on net sales. The partnership centers on Enodia’s Sec61 platform, which is designed to destroy pathologic proteins at the point of synthesis before they can drive disease.
Oct 13, 2026Rasonque, also known as daraxonrasib, targets mutated KRAS and other RAS proteins present in over 90% of pancreatic tumors. Its mechanism differs from KRAS G12C inhibitors by binding RAS in its GTP-bound “on” conformation through a molecular glue interaction with cyclophilin A.
Oct 13, 2026State officials said GSK will begin demolishing existing buildings next year and construct new facilities that support both clinical and commercial supply. The project is expected to create more than 300 new jobs over five years while retaining about 4,500 existing full-time jobs across Pennsylvania.
Oct 12, 2026Roche used the American Academy of Ophthalmology 2026 Annual Meeting to present updated Meerkat and Sandcat data for the IL-6 inhibitor vamikibart in uveitic macular edema. The company said Week 52 results showed numerically higher vision gains versus sham, sustained improvements on vision and macular edema measures, and that about two-thirds of eligible patients required no retreatment after Week 16.
Oct 12, 2026Bristol Myers said both studies met their primary endpoints, but neither topline release fully removed program-specific questions. The immediate significance is strategic: the company needs new products that can contribute as two cornerstone medicines near the ends of their life cycles.
Oct 10, 2026The source describes Lilly as having pulled ahead of Novo in GLP-1s, with Zepbound and Mounjaro generating more than $35 billion last year. It also points to more than $30 billion in 2026 biotech buyouts and new China-focused deals as evidence that Lilly is using current cash flow to widen its future options.
Oct 9, 2026The transaction brings Exparel and Zilretta into Viatris’ portfolio and gives the company established U.S. commercial infrastructure in non-opioid pain. Strategically, the timing matters because Viatris is also awaiting a Dec. 27 FDA decision on its fast-acting meloxicam formulation for moderate-to-severe acute pain.
Oct 9, 2026Newron’s update expands a safety issue that first surfaced with a patient death in April, when the FDA halted further U.S. enrollment in ENIGMA-TRS 2. The strategic question now is whether the company can satisfy the agency on a sodium-channel mechanism concern without slowing a broader Phase 3 effort that still spans an international study and ongoing recruitment outside the U.S.
Oct 9, 2026The setback narrows one of the most visible label-expansion paths for Vyvgart Hytrulo even as argenx keeps other immunology programs moving. It also highlights how difficult Sjogren’s disease remains in late-stage development, where placebo effects and endpoint sensitivity can derail assets that showed earlier promise.
Oct 9, 2026The Dutch ruling bars production, import, stocking or sale of Keytruda SC in Belgium, Denmark, France, Ireland, Italy, Sweden, Switzerland and the Netherlands. Together with an earlier German injunction, the decision disrupts Merck’s effort to move major European markets toward a subcutaneous version protected by different patents than intravenous Keytruda.
Machine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.
FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.